Skip to main content

Advertisement

SpringerLink
Log in

Use of Multiple Biomarkers in Heart Failure

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Biomarkers are becoming increasingly available for clinical use, particularly in the care of patients with heart failure. For health care providers, a major difficulty is how to interpret and apply these increasing amounts of diagnostic and prognostic information. Consequently, the scientific challenge is evolving from the discovery of biomarkers to the selection and validation of select panels of clinically useful markers that balance performance and practicality. Optimal combinations of biomarkers will vary based on the intended use (eg, diagnosis vs prognosis). The final goal must be to generate more actionable knowledge that improves patient management and outcomes, rather than merely creating greater complexity. Here we conceptually define multiple biomarker strategies, provide examples of emerging biomarker panels used in the care of patients with heart failure, and address key statistical and clinical issues for this rapidly evolving field.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as follows: • Of importance

  1. Biomarker Definitions Working Group: Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89–95.

    Article  Google Scholar 

  2. Vasan RS: Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335–2362.

    Article  PubMed  Google Scholar 

  3. Mark DB, Felker GM: B-type natriuretic peptide—a biomarker for all seasons? N Engl J Med 2004, 350:718–720.

    Article  CAS  PubMed  Google Scholar 

  4. Allen LA, Hernandez AF, O’Connor CM, et al.: End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol 2009, 53:2248–2258.

    Article  PubMed  Google Scholar 

  5. Donahue MP, Marchuk DA, Rockman HA: Redefining heart failure: the utility of genomics. J Am Coll Cardiol 2006, 48:1289–1298.

    Article  PubMed  Google Scholar 

  6. Arab S, Gramolini AO, Ping P, et al.: Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol 2006, 48:1733–1741.

    Article  CAS  PubMed  Google Scholar 

  7. • Hlatky MA, Greenland P, Arnett DK, et al.: Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009, 119:2408–2416. This is an expert summary of current concepts and standards for critical appraisal of risk assessment in cardiovascular disease

    Article  PubMed  Google Scholar 

  8. • McGeechan K, Macaskill P, Irwig L, et al.: Assessing new biomarkers and predictive models for use in clinical practice: a clinician’s guide. Arch Intern Med 2008, 168:2304–2310. This paper proposes a framework for how to assess the clinical use of new biomarkers.

    Article  PubMed  Google Scholar 

  9. • Braunwald E: Biomarkers in heart failure. N Engl J Med 2008, 358:2148–2159. This is a general review of existing and emerging biomarkers in heart failure.

    Article  CAS  PubMed  Google Scholar 

  10. Lainscak M, Anker MS, von Haehling S, et al.: Biomarkers for chronic heart failure : diagnostic, prognostic, and therapeutic challenges. Herz 2009, 34:589–593.

    Article  PubMed  Google Scholar 

  11. Allen LA, Michael Felker G: Multi-marker strategies in heart failure: clinical and statistical approaches. Heart Fail Rev 2009 May 3 [Epub ahead of print].

  12. Morrow DA, Braunwald E: Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 2003, 108:250–252.

    Article  PubMed  Google Scholar 

  13. Fonarow GC, Adams KF Jr, Abraham WT, et al.: Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005, 293:572–580.

    Article  CAS  PubMed  Google Scholar 

  14. Newby LK, Storrow AB, Gibler WB, et al.: Bedside multimarker testing for risk stratification in chest pain units: the chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation 2001, 103:1832–1837.

    CAS  PubMed  Google Scholar 

  15. James SK, Lindback J, Tilly J, et al.: Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol 2006, 48:1146–1154.

    Article  CAS  PubMed  Google Scholar 

  16. Sabatine MS, Morrow DA, de Lemos JA, et al.: Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002, 105:1760–1763.

    Article  CAS  PubMed  Google Scholar 

  17. Westerhout CM, Fu Y, Lauer MS, et al.: Short-and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers. J Am Coll Cardiol 2006, 48:939–947.

    Article  PubMed  Google Scholar 

  18. Wilson PW, D'Agostino RB, Levy D, et al.: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837–1847.

    CAS  PubMed  Google Scholar 

  19. Ridker PM, Rifai N, Rose L, et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557–1565.

    Article  CAS  PubMed  Google Scholar 

  20. Ralli S, Horwich TB, Fonarow GC: Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. Am Heart J 2005, 150:1220–1227.

    Article  CAS  PubMed  Google Scholar 

  21. van Kimmenade RR, Januzzi JL, Jr., Baggish AL, et al.: Amino-terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? J Am Coll Cardiol 2006, 48:1621–1627.

    Article  PubMed  CAS  Google Scholar 

  22. Anand IS, Rector T, Latini R, et al.: Do biomarkers add prognostic information to routine measures of the severity of heart failure? J Am Coll Cardiol 2006, 7(4A):A66–A67.

    Google Scholar 

  23. Latini R, Masson S, Anand IS, et al.: Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007, 16:1242–1249.

    Article  CAS  Google Scholar 

  24. Dunlay SM, Gerber Y, Weston SA, et al.: Prognostic value of biomarkers in heart failure: application of novel methods in the community. Circ Heart Fail 2009, 2:393–400.

    Article  CAS  PubMed  Google Scholar 

  25. Levy WC, Mozaffarian D, Linker DT, et al.: The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006, 113:1424–1433.

    Article  PubMed  Google Scholar 

  26. Januzzi JL Jr, Peacock WF, Maisel AS, et al.: Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007, 50:607–613.

    Article  CAS  PubMed  Google Scholar 

  27. Rehman SU, Martinez-Rumayor A, Mueller T, et al.: Clin Chim Acta 2008, 392:41–45.

    Article  CAS  PubMed  Google Scholar 

  28. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al.: Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006, 48:1217–1224.

    Article  PubMed  CAS  Google Scholar 

  29. Maisel AS, Krishnaswamy P, Nowak RM, et al.: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161–167.

    Article  CAS  PubMed  Google Scholar 

  30. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al.: The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005, 95:948–954.

    Article  CAS  PubMed  Google Scholar 

  31. Steinhart B, Thorpe KE, Bayoumi AM, et al.: Improving the diagnosis of acute heart failure using a validated prediction model. J Am Coll Cardiol 2009, 54:1515–1521.

    Article  CAS  PubMed  Google Scholar 

  32. Felker GM, Hasselblad V, Hernandez AF, et al.: Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009, 158:422–430.

    Article  CAS  PubMed  Google Scholar 

  33. Jessup M, Abraham WT, Casey DE, et al.: 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:1977–2016.

    Article  PubMed  Google Scholar 

  34. Deng MC, Eisen HJ, Mehra MR, et al.: Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006, 6:150–160.

    Article  CAS  PubMed  Google Scholar 

  35. Paynter NP, Chasman DI, Pare G, et al.: Association between a literature-based genetic risk score and cardiovascular events in women. JAMA 2010, 303:631–637.

    Article  CAS  PubMed  Google Scholar 

  36. Diamond GA, Denton TA, Berman DS, et al.: Prior restraint: a bayesian perspective on the optimization of technology utilization for diagnosis of coronary artery disease. Am J Cardiol 1995, 76:82–86.

    Article  CAS  PubMed  Google Scholar 

  37. Kattan MW: Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003, 95:634–635.

    Article  CAS  PubMed  Google Scholar 

  38. Cook NR: Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007, 115:928–935.

    Article  PubMed  Google Scholar 

  39. Cook NR, Ridker PM: Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009, 150:795–802.

    PubMed  Google Scholar 

  40. Morrow DA, Antman EM, Charlesworth A, et al.: TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000, 102:2031–2037.

    CAS  PubMed  Google Scholar 

  41. Felker GM, Leimberger JD, Califf RM, et al.: Risk stratification after hospitalization for decompensated heart failure. J Card Fail 2004, 10:460–466.

    Article  PubMed  Google Scholar 

  42. Aaronson KD, Schwartz JS, Chen TM, et al.: Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997, 95:2660–2667.

    CAS  PubMed  Google Scholar 

  43. Atienza F, Martinez-Alzamora N, De Velasco JA, et al.: Risk stratification in heart failure using artificial neural networks. Proc AMIA Symp 2000:32–36.

  44. Ortiz J, Ghefter CG, Silva CE, et al.: One-year mortality prognosis in heart failure: a neural network approach based on echocardiographic data. J Am Coll Cardiol 1995, 26:1586–1593.

    Article  CAS  PubMed  Google Scholar 

  45. Penny W, Frost D: Neural networks in clinical medicine. Med Decis Making 1996, 16:386–398.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

No potential conflict of interest relevant to this article was reported.

Author information

Authors and Affiliations

  1. Division of Cardiology, Colorado Cardiovascular Outcomes Research Consortium and Section of Heart Failure and Cardiac Transplantation, University of Colorado Denver, Academic Office 1, Room 7109, 12631 East 17th Avenue, Mail Stop B130, PO Box 6511, Aurora, CO, 80045, USA

    Larry A. Allen

Authors
  1. Larry A. Allen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Larry A. Allen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Allen, L.A. Use of Multiple Biomarkers in Heart Failure. Curr Cardiol Rep 12, 230–236 (2010). https://doi.org/10.1007/s11886-010-0109-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-010-0109-6

Keywords

Search

Navigation